Mitochondrial
MOTS-c vs SS-31: Research Comparison
MOTS-c and SS-31 represent two distinct approaches to mitochondrial research, each targeting different aspects of cellular energy metabolism. While both peptides focus on mitochondrial function, they operate through fundamentally different mechanisms and have varying levels of clinical validation in research models.
Side-by-side comparison
| Attribute | MOTS-c | SS-31 |
|---|---|---|
| Classification | Mitochondrial-derived peptide | Mitochondria-targeting peptide |
| Mechanism | AMPK pathway activation, metabolic gene modulation | Cardiolipin binding, mitochondrial membrane stabilisation |
| Primary research focus | Metabolic health, exercise performance, aging | Oxidative stress, cardioprotection, neuroprotection |
| Half-life | 4 hours | 4 hours |
| Evidence grade | B - Limited human trials, preliminary data | A - FDA approved as Forzinity (September 2025) |
Detailed analysis
MOTS-c functions as a mitochondrial-derived peptide that influences cellular metabolism primarily through AMPK pathway activation. In research models, this mechanism enhances glucose uptake and fatty acid oxidation whilst modulating metabolic gene expression. Studies indicate MOTS-c promotes mitochondrial biogenesis and improves insulin sensitivity, making it a focus for metabolic health research.
SS-31 operates through a more targeted approach, selectively binding to cardiolipin within the inner mitochondrial membrane. This unique mechanism stabilises mitochondrial structure and reduces reactive oxygen species production. Research demonstrates that SS-31's cardiolipin interaction enhances ATP production and decreases oxidative stress in experimental models.
The fundamental difference lies in their mechanisms: MOTS-c works systemically through metabolic pathway activation, whilst SS-31 targets specific mitochondrial membrane components. MOTS-c research focuses on metabolic disorders, exercise performance, and aging studies. SS-31 research emphasises oxidative stress reduction, cardioprotection, and neuroprotection.
Both compounds share identical pharmacokinetic profiles with 4-hour half-lives and subcutaneous administration routes in research settings. However, their evidence levels differ significantly. SS-31 achieved FDA approval as Forzinity for Barth syndrome in September 2025, representing the first FDA-approved mitochondria-targeted therapeutic. MOTS-c remains in earlier research phases with preliminary human studies showing promising metabolic improvements, though larger trials are needed.
The regulatory landscape also differs: SS-31's approval status contrasts with MOTS-c's current FDA Category 2 classification, though reclassification to Category 1 is expected by February 2026. This distinction reflects the different stages of clinical development and evidence accumulation for each compound in research applications.
Key differences
- ·SS-31 has FDA approval whilst MOTS-c remains in research phases
- ·MOTS-c targets metabolic pathways systemically; SS-31 targets specific mitochondrial membrane components
- ·SS-31 focuses on oxidative stress reduction; MOTS-c emphasises metabolic enhancement
- ·Different regulatory classifications: SS-31 approved therapeutic vs MOTS-c research compound
Research summary
SS-31 research centres on oxidative stress-related conditions and has achieved clinical validation through FDA approval for Barth syndrome. MOTS-c research focuses on metabolic disorders and exercise physiology, with preliminary human studies showing promise but requiring further validation. Both compounds offer distinct approaches to mitochondrial research applications.